AbbVie And ADARx Enter Multi-billion Dollar Partnership To Develop SiRNA Therapies PMLiVE - May 19th, 2025

FDA Approval Expert With 10 Successes Strengthens Aviceda Stock Titan - Apr 9th, 2025

Nanoscope Therapeutics’ Gene Therapy MCO-010 Restores Vision In Patients With Retinitis Pigmentosa CGTLive® - Apr 4th, 2025

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C Financing Round To Advance Lead Program AVD-104 For Geographic Atrophy Into Pivotal Trials Business Wire - Jan 7th, 2025

Nanoscope Announces BLA Submission Plans For Retinitis Pigmentosa Gene Therapy MCO-010 Following Meeting With FDA CGTLive® - Oct 13th, 2024

Phase 2 Trial: ADX-2191 May Improve Retinal Function In Patients With Retinitis Pigmentosa Healio - Jun 29th, 2023

New Insight With Veeral Sheth, MD HCPLive - Jun 6th, 2023

Is Annexin Pharmaceuticals (STO:ANNX) In A Good Position To Deliver On Growth Plans? Simply Wall St - Jan 24th, 2023

ARVO Announces The Winners Of Multiple Awards Ophthalmology Times - Jan 23rd, 2023

Nanocomposite Formulation For Therapy Of Ocular Diseases | IJN Dove Medical Press - Jan 23rd, 2023